CMA considers proposals to address concerns over cash machine deal

Brink’s has offered to sell its UK NoteMachine business and the UK business of TestLink to address the CMA’s competition concerns over its acquisition of NCR Atleos. The companies together operate more than 50% of UK cash machines, and the CMA is concerned the deal could reduce competition in ATM operation and maintenance, potentially limiting options and raising fees. The CMA will consult on the proposed remedies and has not yet accepted them; if satisfied, it could conditionally clear the deal without a phase 2 investigation.

Analysis

The key value driver is not the divestiture headline but whether the remedies preserve a credible UK rival. A buyer with operational capability and access to spare parts could keep NoteMachine competitive; a weak buyer or delayed transfer could leave the merged Brink’s/NCR Atleos with substantial market power despite formal clearance. Third-party feedback and the CMA’s view of the buyer are therefore the next information catalysts.

Near term, conditional clearance would reduce the risk of a prolonged phase 2 review and deal delay for BCO and NATL. For BCO, however, that certainty is purchased through a forced disposal; proceeds, stranded costs and the businesses’ contribution are not provided, so the net effect on value cannot be quantified. NATL avoids an outright blocked deal but should not be valued as though the combined UK footprint were unconstrained. Any pricing-power benefit is also vulnerable to customer switching, alternative cash-access channels and scrutiny of fees.

Over 1–3 months, watch consultation feedback, remedy wording and buyer approval. Over 6–18 months, test whether service continuity and independent competition persist; a nominally independent operation without parts access or effective scale may not constrain pricing. The thesis weakens if the CMA rejects or materially expands remedies, or if the approved buyer cannot sustain the business. No company-specific valuation or deal economics are supplied, so the regulatory update alone is not enough to establish a mispricing.

Key Decisions for Investors

• No immediate directional trade: keep BCO and NATL on event watch until the CMA consults and confirms both remedy scope and buyer suitability; the missing deal economics and divested-unit financials make the net earnings impact unclear.
• If the CMA accepts the current package without material expansion, consider a tactical long NATL / short BCO relative-value position only if market pricing does not already reflect improved closing certainty. Keep sizing small: both benefit from avoiding phase 2, while BCO bears the direct asset-sale impact.
• Track consultation responses, formal undertakings, buyer capability and transfer arrangements for NoteMachine and TestLink. A credible buyer with continuity of operations and parts supply supports clearance without hollowing out competition; a weak buyer or remedy expansion is a negative catalyst for deal completion and valuation.
• Reassess if the CMA rejects the undertakings or requires broader divestitures; conversely, formal acceptance and evidence that the buyer can operate independently would reduce regulatory risk. Do not underwrite higher UK pricing or margins absent post-close evidence of customer retention, service performance and fee behavior.